PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/50, 31/505, 31/42

A1

(11) International Publication Number: **WO 00/15230**

(43) International Publication Date: 23 March 2000 (23.03.00)

(21) International Application Number: PCT/US99/21069

(22) International Filing Date: 13 September 1999 (13.09.99)

(30) Priority Data:
60/100,677 17 September 1998 (17.09.98) US

(71) Applicant: BRISTOL–MYERS SQUIBB COMPANY [–/US]; P.O. Box 4000, Princeton, NJ 08543–4000 (US).

(72) Inventors: ROBL, Jeffrey, A.; 7 Tulip Drive, Newtown, PA 18940 (US). PARKER, Rex, A.; 147 Church Road, Titusville, NJ 08560 (US). BILLER, Scott, A.; 31 Second Street, Hopewell, NJ 08525 (US). JAMIL, Haris; 239 Burgundy Lane, Newtown, PA 18940 (US). JACOBSON, Bruce, L.; 368 Vetterlein Avenue, Mercerville, NJ 08619 (US). KODUKULA, Krishna; 33 Douglas Drive, Princeton, NJ 08540 (US).

(74) Agents: RODNEY, Burton et al.; Bristol–Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543–4000 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

(57) Abstract

A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.